In order to validate the location and degree of thrombus, patients receive comprehensive clinical evaluation and imaging studies prior to the treatment. Medication may be changed, and informed consent is acquired.
Depending on the location of the thrombus, venous access is usually obtained via the common femoral, popliteal, or jugular vein under sterile procedure and local anesthetic. To guarantee a safe puncture, ultrasound guidance is often utilized.
Using fluoroscopic or ultrasound guidance, a multi-side-hole infusion catheter is advanced over a guidewire that has been inserted through the needle to the thrombus location.
Initially, thrombolytic medicines (such as alteplase/tPA) may be delivered directly into the thrombus using a "pulse spray" approach to increase penetration by creating fissures.
Following the initial spray, the thrombolytic agent is continuously infused through the catheter for 12 to 24 hours or longer, depending on the patient's reaction and the clot burden, under close observation.
Thrombus dissolving can be enhanced by mechanical thrombectomy devices like AngioJet or ultrasound-assisted thrombolysis (e.g., EKOS catheter), which increases effectiveness and shortens infusion time.
During infusion, vital signs, coagulation parameters, and neurological condition are closely monitored in order to identify and treat bleeding or other issues as soon as possible.
Following enough clot destruction, the thrombolytic infusion is discontinued, the catheter and sheath are carefully withdrawn, and closure devices or manual compression are used to establish hemostasis.
To assess clot resolution, further imaging is performed. If vein stenosis continues, additional endovascular treatments like angioplasty or stenting may be carried out.
In order to prevent re-thrombosis and evaluate symptom improvement, patients typically continue on anticoagulant treatment after the surgery and need close clinical follow-up.
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
CDT is particularly beneficial for patients with acute thrombosis (less than 21 days after the onset of symptoms) involving the iliac and proximal femoral veins. This group is more likely to experience severe symptoms of post-thrombotic syndrome (PTS).
Compared to anticoagulation alone, CDT lowers the risk or severity of PTS by protecting venous valves and reducing clot burden.
recommended in extreme situations where venous gangrene or impaired blood flow pose a risk of limb ischemia and necessitate quick clot removal.
When conventional treatment is ineffective, very symptomatic individuals with subacute or chronic venous clots may be candidates for CDT.
The term “acute” or “subacute” inferior vena cava (IVC) thrombosis refers to thrombosis that affects the major central veins, especially if it is symptomatic or poses a risk to limbs.
CDT is used to actively lyse the thrombus when anticoagulation is not enough.
The long-term decrease in PTS and enhanced venous patency provided by CDT are particularly beneficial to these individuals.
Recent major surgery, recent stroke, and active internal bleeding are absolute contraindications. Benefits and relative hazards must be taken into account.
By immediately delivering thrombolytic drugs to the clot location, CDT promptly restores circulation and relieves symptoms like pain, edema, and limb dysfunction.
Compared to anticoagulation alone, CDT significantly reduces the risk and severity of chronic PTS by dissolving more of the clot burden and preserving venous valve function.
DVT CDT lowers the residual clot load, which results in fewer deep vein thrombosis episodes and venous disease rehospitalizations in the future.
By targeting the clot with smaller doses of lytic medications than systemic thrombolysis, CDT reduces the risk of significant bleeding and other systemic effects.
Vein patency, symptom alleviation, and long-term capacity to resume daily activities with fewer chronic problems are all improved in patients treated with CDT.
Compared to standard surgical thrombectomy, CDT frequently results in shorter hospital stays and faster recovery times with fewer skin incisions that don’t require stitches.
Particularly for younger patients with longer life expectancies, CDT may lower long-term impairment, recurrence rates, and expenses related to PTS and recurrent hospital stays.
702, 7th Floor, Solaris Kode, Near Khatu Shyam Temple, VIP Road, Vesu , Surat.
drjennygandhi98@gmail.com
+91 90033 03373
